Lite Strategy LITS
NASDAQ LITS
$0.99 +0.05 (+4.91%)
At close: Aug 21, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Non-Current Deffered Revenue (2016 - 2023)

Lite Strategy (LITS) posted quarterly Non-Current Deffered Revenue of $64.5 million for Q2 2023, down 28.77% year-over-year from $90.6 million in Q2 2022, and little changed quarter-over-quarter from $64.5 million in Q1 2023.

Lite Strategy (LITS) Non-Current Deffered Revenue (2016 - 2023) Analysis & Trends

Lite Strategy's Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $64.5 million for Q2 2023.

  • In Q2 2023, Non-Current Deffered Revenue fell 28.77% year-over-year to $64.5 million; the TTM figure through Jun 2023 stood at $64.5 million (down 28.77% YoY), while the FY2023 annual figure was $64.5 million, down 28.77% from the prior year.
  • Non-Current Deffered Revenue for Q2 2023 stood at $64.5 million, roughly flat from $64.5 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $94.3 million in Q3 2021, with the low at $2.8 million in Q1 2020.
  • The 5-year median for Non-Current Deffered Revenue is $69.6 million (2021), against an average of $54.4 million.
  • The sharpest annual moves came in 2019 and 2020: Non-Current Deffered Revenue plunged 39.78% in 2019, then surged 2682.12% in 2020.
  • Lite Strategy's Non-Current Deffered Revenue stood at $3.1 million in 2019, then soared by 2329.38% to $75.5 million in 2020, then climbed by 22.23% to $92.3 million in 2021, then sank by 30.07% to $64.5 million in 2022, then changed by 0.0% to $64.5 million in 2023.
  • Business Quant data shows LITS's Non-Current Deffered Revenue at $64.5 million in Q2 2023, $64.5 million in Q1 2023, and $64.5 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 220.40 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 147.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Lite Strategy 35.71 Mn 28.17 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2023 64.55 Mn
Mar 31, 2023 64.55 Mn
Dec 31, 2022 64.55 Mn
Sep 30, 2022 89.97 Mn
Jun 30, 2022 90.61 Mn
Mar 31, 2022 91.92 Mn
Dec 31, 2021 92.29 Mn
Sep 30, 2021 94.33 Mn
Jun 30, 2021 74.70 Mn
Mar 31, 2021 4.30 Mn
Dec 31, 2020 75.51 Mn
Sep 30, 2020 76.98 Mn
Jun 30, 2020 78.43 Mn
Mar 31, 2020 2.82 Mn
Dec 31, 2019 3.11 Mn
Sep 30, 2019 3.23 Mn
Jun 30, 2019 2.82 Mn
Mar 31, 2019 4.22 Mn
Dec 31, 2018 5.16 Mn
Sep 30, 2016 1.49 Mn